Following the transaction, Amylin
will convert into a subsidiary of its new owner, Bristol-Myers Squibb said.
Pharmaceuticals Inc (San Diego CA) and Eli Lilly & Co's (Indianapolis IN) long-acting Byetta may be tied to increased cancer risk, a top US regulator said, raising concerns that the experimental diabetes drug may need strict warnings.
There is an enormous unmet need to help reduce the individual and economic burden of obesity," comments Christian Weyer, vice president of medical development at Amylin
amp; LONDON -- Bristol-Myers Squibb Company (NYSE:BMY) and AstraZeneca (LSE:AZN) announced that following the successful completion of the acquisition of Amylin
Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.
M2 EQUITYBITES-December 27, 2012-Takeda Pharmaceutical Company and Amylin
Pharmaceuticals withdraw global agreement(C)2012 M2 COMMUNICATIONS http://www.
M2 PHARMA-July 2, 2012-Bristol-Myers Squibb acquires Amylin
Pharmaceutical for USD7.
2 July 2012 - US pharmaceutical group Bristol-Myers Squibb Co (NYSE:BMY) said it had struck an agreement to take over diabetes-focused biopharmaceutical firm Amylin
Pharmaceuticals Inc (NASDAQ:AMLN) at USD31.
Byetta gained a new marketing approval during the quarter, as the Food and Drug Administration allowed Amylin
to market it as a stand-alone treatment for diabetes.
Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company ("Bristol-Myers Squibb") through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin
Most recently, Bradbury served as CEO of Amylin
Pharmaceuticals Inc from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012.
23 April 2012 a[euro]" US drug maker Amylin
Pharmaceuticals Inc (NASDAQ:AMLN) has hired Credit Suisse Group AG (NYSE:CS) and Goldman Sachs Group Inc (NYSE:GS) to seek takeover offers, Bloomberg reported Monday, citing an insider.
30 January 2012 - US Amylin
Pharmaceuticals Inc (NASDAQ:AMLN) and Irish Alkermes plc (NASDAQ:ALKS) said on Friday that the once-weekly treatment for Type 2 diabetes, BYDUREON (exenatide extended-release for injectable suspension), has been approved in the US.